Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
German chamomile extract, derived from the flowers of *Matricaria chamomilla*, is a complex botanical preparation utilized for its therapeutic anxiolytic, anti-inflammatory, and spasmolytic effects. Its pharmacodynamic profile is driven by several key bioactive constituents, most notably the flavonoid apigenin and the sesquiterpenes chamazulene and α-bisabolol. Apigenin functions as a ligand for central benzodiazepine receptors, acting as a positive allosteric modulator of the GABA-A receptor to induce mild sedation and reduce anxiety without the significant side effects associated with synthetic benzodiazepines. Additionally, the extract exhibits potent anti-inflammatory properties by inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) pathways, which reduces the synthesis of pro-inflammatory prostaglandins and leukotrienes. It is widely applied in both clinical and traditional settings for the treatment of generalized anxiety disorder, gastrointestinal spasms, and various inflammatory conditions of the skin and mucous membranes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on german chamomile extract.